Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy

We describe 2 patients with NSCLC harboring EGFR fusion mutations (EGFR-MACF1 and EGFR-GNAT3) combined with EGFR amplification. Both patients received EGFR-TKI treatment, and 1 of them showed an antitumor response.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research